BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Direct Healthcare Professional Communication on Opzelura 15 mg/g cream: Important information regarding presence of particles in Opzelura cream

Active substance: Ruxolitinib phosphate

The company Incyte Biosciences Distribution B.V. informs about possible particles in Opzelura 15 mg/g cream, which may form during production from the active substance. Patients should discontinue use if they notice particles and contact the dispensing pharmacy to receive a replacement free of charge.

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 154KB, File does not meet accessibility standards